Catheter Sclerotherapy for Abdominal Abscess
(ABCS Trial)
Trial Summary
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Catheter Sclerotherapy for Abdominal Abscess?
Catheter-directed sclerotherapy has been used effectively for treating chronic venous leg ulcers and involves delivering a sclerosing agent (a substance that causes blood vessels to shrink) directly to the target area. This suggests that a similar approach could potentially be effective for treating abdominal abscesses by targeting and reducing the abscess.12345
Is catheter sclerotherapy for abdominal abscess safe?
How is Catheter Sclerotherapy different from other treatments for abdominal abscesses?
Catheter Sclerotherapy is unique because it involves using a catheter to directly deliver a sclerosing agent (a substance that causes tissue to harden) into the abscess, which can help shrink it. This method is minimally invasive compared to traditional surgery and may offer a quicker recovery with fewer complications.611121314
What is the purpose of this trial?
This is a single center, two arm phase I/II clinical trial exploring the use of chemical sclerosants (ethanol and povidone iodine) in decreasing the time needed for catheter drainage for patients with non-fistulous intraabdominal abscesses. The target study sample size is 60 patients, 30 in each arm and abscess size is to be a minimum of 3cm in all 3 dimensions. The primary outcomes of interest will be tolerability and need for catheter reinsertion by one week post intervention.
Research Team
Junaid Raja, MD, MSPH, FACP
Principal Investigator
University of Alabama at Birmingham
Eligibility Criteria
This trial is for patients with non-fistulous intraabdominal abscesses that are at least 3cm in size. Participants must be suitable for catheter drainage and not have any conditions that would exclude them from the study, such as fistulas or allergies to the sclerosants used.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Catheter-based drainage and sclerotherapy using povidone iodine or ethanol for non-fistulous intraabdominal abscesses
Follow-up
Participants are monitored for tolerability and need for catheter reinsertion
Treatment Details
Interventions
- Catheter Sclerotherapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
Argon Medical Devices
Industry Sponsor